Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

Blood blood.2024024300.

https://doi.org/10.1182/blood.2024024300

Published: 2024

Includes: Supplemental data

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

James A Kuzich, Laure Talarmain, Dane Vassiliadis, Andrew A Guirguis, Jack D Chan, Paul A Beavis, Phillip K Darcy, Ashley P Ng, Mark A Dawson

Blood (2023) 142 (Supplement 1): 887.

https://doi.org/10.1182/blood-2023-191111

Published: 2023

Journal Articles

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Thomas E Lew, Mark Van Delft, Chris Riffkin, Georgiou Angela, Christine White, Yin Yuan, Jahja Michelle, Mary Ann Anderson, Rachel Thijssen, David C.S. Huang, Mark A Dawson, Andrew W. Roberts

Blood (2023) 142 (Supplement 1): 415.

https://doi.org/10.1182/blood-2023-184392

Published: 2023

Journal Articles

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Blood (2022) 140 (Supplement 1): 1009–1010.

https://doi.org/10.1182/blood-2022-162930

Published: 2022

Journal Articles

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Blood (2021) 138 (Supplement 1): 267.

https://doi.org/10.1182/blood-2021-145424

Published: 2021

Journal Articles

Epigenetic therapies in acute myeloid leukemia: where to from here?

Katie A. Fennell, Charles C. Bell, Mark A. Dawson

Blood (2019) 134 (22): 1891–1901.

https://doi.org/10.1182/blood.2019003262

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Blood (2017) 129 (21): 2882–2895.

https://doi.org/10.1182/blood-2016-05-718171

Published: 2017

Includes: Supplemental data

Journal Articles

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q. Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A. Dawson, Sarah-Jane Dawson

Blood (2017) 129 (12): 1685–1690.

https://doi.org/10.1182/blood-2016-09-740308

Published: 2017

Includes: Supplemental data

Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD

Blood (2016) 128 (22): 5223.

https://doi.org/10.1182/blood.V128.22.5223.5223

Published: 2016

Journal Articles

Modelling Resistance to Emerging Epigenetic Therapies

Blood (2014) 124 (21): 3546.

https://doi.org/10.1182/blood.V124.21.3546.3546

Published: 2014

Journal Articles

Nuclear JAK2

Mark A. Dawson, Andrew J. Bannister, Lindsay Saunders, Omar-Abdel Wahab, Fan Liu, Stephen D. Nimer, Ross L. Levine, Berthold Göttgens, Tony Kouzarides, Anthony R. Green

Blood (2011) 118 (26): 6987–6988.

https://doi.org/10.1182/blood-2011-10-385278

Published: 2011

Journal Articles

Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia

Blood (2011) 118 (21): 55.

https://doi.org/10.1182/blood.V118.21.55.55

Published: 2011

Journal Articles

Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm

Philip A. Beer, François Delhommeau, Jean-Pierre LeCouédic, Mark A. Dawson, Edwin Chen, David Bareford, Rajko Kušec, Mary Frances McMullin, Claire N. Harrison, Alessandro M. Vannucchi, William Vainchenker, Anthony R. Green

Blood (2010) 115 (14): 2891–2900.

https://doi.org/10.1182/blood-2009-08-236596

Published: 2010

Journal Articles

ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling

Andrew D. Wood, Edwin Chen, Ian J. Donaldson, Shilpa Hattangadi, Karly A. Burke, Mark A. Dawson, Diego Miranda-Saavedra, Harvey F. Lodish, Anthony R. Green, Berthold Göttgens

Blood (2009) 114 (9): 1820–1830.

https://doi.org/10.1182/blood-2009-02-206573

Published: 2009

Includes: Supplemental data

Journal Articles

The transcriptional program controlled by the stem cell leukemia gene Scl/Tal1 during early embryonic hematopoietic development

Nicola K. Wilson, Diego Miranda-Saavedra, Sarah Kinston, Nicolas Bonadies, Samuel D. Foster, Fernando Calero-Nieto, Mark A. Dawson, Ian J. Donaldson, Stephanie Dumon, Jonathan Frampton, Rekin's Janky, Xiao-Hong Sun, Sarah A. Teichmann, Andrew J. Bannister, Berthold Göttgens

Blood (2009) 113 (22): 5456–5465.

https://doi.org/10.1182/blood-2009-01-200048

Published: 2009

Includes: Supplemental data

Journal Articles

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia

Alberto Catalano, Mark A. Dawson, Karthiga Somana, Stephen Opat, Anthony Schwarer, Lynda J. Campbell, Harry Iland

Blood (2007) 110 (12): 4073–4076.

https://doi.org/10.1182/blood-2007-06-095554

Published: 2007

Includes: Supplemental data

Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green

Blood (2007) 110 (11): 3537.

https://doi.org/10.1182/blood.V110.11.3537.3537

Published: 2007

NARROW

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Epigenetic therapies in acute myeloid leukemia: where to from here?

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Modelling Resistance to Emerging Epigenetic Therapies

Nuclear JAK2

Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia

Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm

ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling

The transcriptional program controlled by the stem cell leukemia gene Scl/Tal1 during early embryonic hematopoietic development

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only